Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vertex Pharmaceuticals
(NQ:
VRTX
)
463.15
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Vertex Pharmaceuticals
< Previous
1
2
3
4
5
6
Next >
Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor in Children With Cystic Fibrosis Ages 6 Through 11
November 12, 2021
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Reports Third-Quarter 2021 Financial Results
November 02, 2021
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex and Mammoth Biosciences Announce Collaboration to Develop In Vivo Gene-Editing Therapies for Serious Diseases
October 26, 2021
From
Mammoth Biosciences
Via
Business Wire
Vertex to Announce Third-Quarter 2021 Financial Results on November 2
October 22, 2021
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex to Present Long-Term Data Demonstrating Significant Benefits of Treatment With CFTR Modulators at North American Cystic Fibrosis Conference (NACFC)
October 19, 2021
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes
October 18, 2021
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on September 15th
September 13, 2021
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Announces Publication in The New England Journal of Medicine of Phase 3 Results for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People With Cystic Fibrosis
August 26, 2021
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Appoints Stuart A. Arbuckle as Chief Operating Officer
August 04, 2021
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Reports Second-Quarter 2021 Financial Results
July 29, 2021
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex to Initiate Phase 3 Development Program for New Once-Daily Triple Combination Regimen in People With Cystic Fibrosis
July 28, 2021
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain
July 19, 2021
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex to Announce Second-Quarter 2021 Financial Results on July 29
July 16, 2021
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Announces National Reimbursement Agreement in France for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) and SYMKEVI® (tezacaftor/ivacaftor) for Eligible Cystic Fibrosis Patients
June 28, 2021
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Announces New Portfolio Reimbursement Agreement in Italy Including KAFTRIO®, SYMKEVI® and Additional Indications of ORKAMBI® and KALYDECO® for Eligible Patients With Cystic Fibrosis
June 25, 2021
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older Who Have at Least One F508del Mutation
June 18, 2021
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting
June 11, 2021
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Announces Primary Endpoint Achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency
June 10, 2021
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
CORRECTING and REPLACING Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
June 09, 2021
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
June 09, 2021
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex to Present at the Bank of America Securities 2021 Virtual Health Care Conference on May 13
May 10, 2021
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Reports First-Quarter 2021 Financial Results
April 29, 2021
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing
April 22, 2021
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex to Announce First-Quarter 2021 Financial Results on April 29
April 19, 2021
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.